Blood ketone bodies in congestive heart failure

Division of Cardiology (Department of Medicine), Helsinki University Central Hospital, Finland.

OBJECTIVES: The present study was designed to assess whether blood ketone bodies are elevated in congestive heart failure (CHF) and whether ketonemia is related to the hemodynamic and neurohumoral abnormalities of CHF. BACKGROUND: In CHF, consumption of the body's fat stores may become abnormally high, contributing to the development of cardiac cachexia. Increased mobilization of free fatty acids could, in theory, augment ketogenesis, but whether patients with CHF are prone to ketosis remains unknown. METHODS: Forty-five patients with chronic CHF (mean age [+/- SD] 57 +/- 13 years) and 14 control subjects free of CHF (mean age 53 +/- 13 years) underwent invasive and noninvasive cardiac studies and determination of blood ketone bodies (acetoacetate plus beta-hydroxybutyrate), circulating free fatty acids, glucose, lactate, insulin, glucagon, growth hormone, cortisol, norepinephrine, N-terminal proatrial natriuretic peptide, tumor necrosis factor-alpha and interleukin-6 after an overnight fast. RESULTS: Patients with CHF had elevated blood ketone bodies (median 267 mumol/liter, range 44 to 952) compared with control subjects (median 150 mumol/liter, range 31 to 299, p < 0.05). In the total study group, blood ketone bodies were related to pulmonary artery wedge pressure (r5 = 0.45, p < 0.001), left ventricular ejection fraction (r3 = -0.37, p < 0.01), right atrial pressure (r3 = 0.36, p < 0.01) and circulating concentrations of free fatty acids (r5 = 0.52, p < 0.001), glucose (r5 = -0.39, p < 0.001), norepinephrine (r3 = 0.45, p < 0.001), growth hormone (r5 = 0.30, p < 0.05) and interleukin-6 (r3 = 0.27, p < 0.05). In multivariate analysis, left ventricular ejection fraction, serum free fatty acids and serum glucose were independent predictors of ketonemia. CONCLUSIONS: Blood ketone bodies are elevated in CHF in proportion to the severity of cardiac dysfunction and neurohormonal activation. This may be at least partly attributable to increased free fatty acid mobilization in response to augmented neurohormonal stimulation. Additional studies are needed to identify the detailed mechanisms and clinical implications of CHF ketosis.

This article has been cited by other articles:

				G. Fragasso, A. Salerno, G. Lattuada, A. Cuko, G. Calori, A. Scollo, F. Ragogna, F. Arioli, G. Bassanelli, R. Spoladore, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure Heart, September 15, 2011; 97(18): 1495 - 1500. [Abstract] [Full Text] [PDF]

				V. Lionetti, W. C. Stanley, and F. A. Recchia Modulating fatty acid oxidation in heart failure Cardiovasc Res, May 1, 2011; 90(2): 202 - 209. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley Myocardial Fatty Acid Metabolism in Health and Disease Physiol Rev, January 1, 2010; 90(1): 207 - 258. [Abstract] [Full Text] [PDF]

				F. Strasser 10.3.1 Classification and pathophysiology of the anorexia-cachexia syndrome Oxford Textbook of Palliative Medicine, January 1, 2010; 4(1): med-9780198570295-chapter - med-9780198570295-chapter. [Abstract] [Full Text]

				H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]

				A. Pelletier and L. Coderre Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1325 - E1332. [Abstract] [Full Text] [PDF]

				G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]

				A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart Cardiovasc Res, July 1, 2006; 71(1): 149 - 157. [Abstract] [Full Text] [PDF]

				W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]

				R. Aquilani, C. Opasich, M. Dossena, P. Iadarola, A. Gualco, P. Arcidiaco, S. Viglio, F. Boschi, M. Verri, and E. Pasini Increased skeletal muscle amino acid release with light exercise in deconditioned patients with heart failure J. Am. Coll. Cardiol., January 4, 2005; 45(1): 158 - 160. [Full Text] [PDF]

				S. A. Jortani, S. D. Prabhu, and R. Valdes Jr Strategies for Developing Biomarkers of Heart Failure Clin. Chem., February 1, 2004; 50(2): 265 - 278. [Abstract] [Full Text] [PDF]

				W. C. Stanley, S. R. Meadows, K. M. Kivilo, B. A. Roth, and G. D. Lopaschuk {beta}-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1626 - H1631. [Abstract] [Full Text] [PDF]

				A. Tardif, N. Julien, A. Pelletier, G. Thibault, A. K. Srivastava, J.-L. Chiasson, and L. Coderre Chronic exposure to beta -hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1205 - E1212. [Abstract] [Full Text] [PDF]

				C.-W. Kong, T.-G. Hsu, F.-J. Lu, W.-L. Chan, and K. Tsai Leukocyte mitochondria depolarization and apoptosis in advanced heart failure: clinical correlations and effect of therapy J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1693 - 1700. [Abstract] [Full Text] [PDF]

				C Berry and A.L Clark Catabolism in chronic heart failure Eur. Heart J., April 1, 2000; 21(7): 521 - 532. [PDF]